{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T11:33:59Z","timestamp":1784892839324,"version":"3.55.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100019139","name":"Life Sciences, University of California, Los Angeles","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019139","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgpath.theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Pathology Clinics"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.path.2026.01.010","type":"journal-article","created":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T03:47:29Z","timestamp":1772855249000},"page":"297-307","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Oncogenicity and Therapeutic Implications of Molecular Biomarkers in Colorectal Carcinoma"],"prefix":"10.1016","volume":"19","author":[{"given":"Mark G.","family":"Evans","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaclyn F.","family":"Hechtman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.path.2026.01.010_bib1","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1136\/gutjnl-2022-327736","article-title":"Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN","volume":"72","author":"Morgan","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.path.2026.01.010_bib2","series-title":"Robbins & Cotran pathologic basis of disease","author":"Kumar","year":"2021"},{"issue":"2","key":"10.1016\/j.path.2026.01.010_bib3","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1053\/j.gastro.2019.08.059","article-title":"Pathways of colorectal carcinogenesis","volume":"158","author":"Nguyen","year":"2020","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.path.2026.01.010_bib4","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1073\/pnas.040564697","article-title":"APC mutations are sufficient for the growth of early colorectal adenomas","volume":"97","author":"Lamlum","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"10.1016\/j.path.2026.01.010_bib5","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/ijc.10630","article-title":"Elevated protein expression of cyclin D1 and Fra-1 but decreased expression of c-Myc in human colorectal adenocarcinomas overexpressing beta-catenin","volume":"101","author":"Wang","year":"2002","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.path.2026.01.010_bib6","first-page":"553","article-title":"Frequent alterations of the beta-catenin and TCF-4 genes, but not of the APC gene, in colon cancers with high-frequency microsatellite instability","volume":"20","author":"Fukushima","year":"2001","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"10.1016\/j.path.2026.01.010_bib7","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.bbrc.2014.04.014","article-title":"A de novo germline mutation of APC for inheritable colon cancer in a Chinese family using multigene next generation sequencing","volume":"447","author":"Zhang","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"10.1016\/j.path.2026.01.010_bib8","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1159\/000363221","article-title":"Familial adenomatous polyposis in three generations of a single family: a case study","volume":"7","author":"Murgic","year":"2014","journal-title":"Case Rep Oncol"},{"issue":"7407","key":"10.1016\/j.path.2026.01.010_bib9","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nature11252","article-title":"Comprehensive molecular characterization of human colon and rectal cancer","volume":"487","year":"2012","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.path.2026.01.010_bib10","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nm1087","article-title":"Cancer genes and the pathways they control","volume":"10","author":"Vogelstein","year":"2004","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.path.2026.01.010_bib11","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-11-2612","article-title":"A comprehensive survey of Ras mutations in cancer","volume":"72","author":"Prior","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.path.2026.01.010_bib12","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1146\/annurev-pathol-011110-130235","article-title":"Molecular genetics of colorectal cancer annual review of pathology mechanisms of disease","volume":"6","author":"Fearon","year":"2011","journal-title":"Annu Rev Pathol"},{"issue":"4","key":"10.1016\/j.path.2026.01.010_bib13","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/jmcb\/mjy075","article-title":"Mutant p53 in colon cancer","volume":"11","author":"Nakayama","year":"2019","journal-title":"J Mol Cell Biol"},{"issue":"1","key":"10.1016\/j.path.2026.01.010_bib14","first-page":"19","article-title":"Genetic alterations in colorectal cancer","volume":"5","author":"Armaghany","year":"2012","journal-title":"Gastrointest Cancer Res"},{"issue":"5","key":"10.1016\/j.path.2026.01.010_bib15","first-page":"585","article-title":"Epigenetic alterations in colorectal cancer: the CpG island methylator phenotype","volume":"28","author":"Bae","year":"2013","journal-title":"Histol Histopathol"},{"issue":"8","key":"10.1016\/j.path.2026.01.010_bib16","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.3748\/wjg.v20.i8.1940","article-title":"Telomeres, telomerase and colorectal cancer","volume":"20","author":"Bertorelle","year":"2014","journal-title":"World J Gastroenterol"},{"issue":"24","key":"10.1016\/j.path.2026.01.010_bib17","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1200\/JCO.21.02691","article-title":"Mismatch repair-deficient colorectal cancer: building on checkpoint blockade","volume":"40","author":"Jin","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.path.2026.01.010_bib18","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.3892\/ijo.2015.3119","article-title":"Deficient mismatch repair: read all about it","volume":"47","author":"Richman","year":"2015","journal-title":"Int J Oncol"},{"key":"10.1016\/j.path.2026.01.010_bib19","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1186\/1471-2407-10-303","article-title":"Mutations in TGFbeta-RII and BAX mediate tumor progression in the later stages of colorectal cancer with microsatellite instability","volume":"10","author":"Yashiro","year":"2010","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.path.2026.01.010_bib20","doi-asserted-by":"crossref","first-page":"777-e17","DOI":"10.1053\/j.gastro.2015.07.036","article-title":"American Gastroenterological Association Institute guideline on the diagnosis and management of Lynch syndrome","volume":"149","author":"Rubenstein","year":"2015","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.path.2026.01.010_bib21","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s10689-012-9591-x","article-title":"EPCAM deletion carriers constitute a unique subgroup of Lynch syndrome patients","volume":"12","author":"Ligtenberg","year":"2013","journal-title":"Fam Cancer"},{"issue":"5","key":"10.1016\/j.path.2026.01.010_bib22","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1053\/j.gastro.2022.08.058","article-title":"Lynch syndrome genetics and clinical implications","volume":"164","author":"Peltom\u00e4ki","year":"2023","journal-title":"Gastroenterology"},{"issue":"83","key":"10.1016\/j.path.2026.01.010_bib23","doi-asserted-by":"crossref","first-page":"35458","DOI":"10.18632\/oncotarget.26249","article-title":"Constitutional mismatch repair-deficiency: current problems and emerging therapeutic strategies","volume":"9","author":"Abedalthagafi","year":"2018","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.path.2026.01.010_bib24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41436-019-0596-9","article-title":"Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the prospective Lynch syndrome database","volume":"22","author":"Dominguez-Valentin","year":"2020","journal-title":"Genet Med"},{"issue":"6","key":"10.1016\/j.path.2026.01.010_bib25","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0016-5085(99)70510-X","article-title":"New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International collaborative group on HNPCC","volume":"116","author":"Vasen","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.path.2026.01.010_bib26","unstructured":"National Comprehensive Cancer Network\u00ae. NCCN Guidelines Colon Cancer. Version 4.2025. 27 JUN 2025."},{"issue":"5109","key":"10.1016\/j.path.2026.01.010_bib27","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1126\/science.8484121","article-title":"Clues to the pathogenesis of familial colorectal cancer","volume":"260","author":"Aaltonen","year":"1993","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.path.2026.01.010_bib28","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.molcel.2014.08.010","article-title":"The BRAF oncoprotein functions through the transcriptional repressor MAFG to mediate the CpG Island Methylator phenotype","volume":"55","author":"Fang","year":"2014","journal-title":"Mol Cell"},{"issue":"4","key":"10.1016\/j.path.2026.01.010_bib29","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1086\/323658","article-title":"The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas","volume":"69","author":"Cunningham","year":"2001","journal-title":"Am J Hum Genet"},{"issue":"11","key":"10.1016\/j.path.2026.01.010_bib30","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1038\/nm.3967","article-title":"The consensus molecular subtypes of colorectal cancer","volume":"21","author":"Guinney","year":"2015","journal-title":"Nat Med"},{"issue":"22","key":"10.1016\/j.path.2026.01.010_bib31","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1200\/JCO.18.02258","article-title":"Impact of consensus molecular subtype on survival in patients with metastatic colorectal cancer: results from CALGB\/SWOG 80405 (Alliance)","volume":"37","author":"Lenz","year":"2019","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.path.2026.01.010_bib32","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1038\/bjc.2014.133","article-title":"Prognostic impact of genomic instability in colorectal cancer","volume":"110","author":"Hveem","year":"2014","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.path.2026.01.010_bib33","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12957-019-1706-5","article-title":"Is microsatellite instability-high really a favorable prognostic factor for advanced colorectal cancer? A meta-analysis","volume":"17","author":"Wang","year":"2019","journal-title":"World J Surg Oncol"},{"issue":"26","key":"10.1016\/j.path.2026.01.010_bib34","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.path.2026.01.010_bib35","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.path.2026.01.010_bib36","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2017.76.9901","article-title":"Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient\/microsatellite instability-high metastatic colorectal cancer","volume":"36","author":"Overman","year":"2018","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.path.2026.01.010_bib37","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S1470-2045(22)00197-8","article-title":"Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a randomised, open-label, phase 3 study","volume":"23","author":"Diaz","year":"2022","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.path.2026.01.010_bib38","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/jnci\/djh034","article-title":"Revised Bethesda guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability","volume":"96","author":"Umar","year":"2004","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.path.2026.01.010_bib39","doi-asserted-by":"crossref","first-page":"610","DOI":"10.21037\/jgo.2018.05.06","article-title":"Beyond microsatellite testing: assessment of tumor mutational burden identifies subsets of colorectal cancer who may respond to immune checkpoint inhibition","volume":"9","author":"Fabrizio","year":"2018","journal-title":"J Gastrointest Oncol"},{"issue":"10","key":"10.1016\/j.path.2026.01.010_bib40","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol"},{"issue":"20","key":"10.1016\/j.path.2026.01.010_bib41","doi-asserted-by":"crossref","first-page":"4623","DOI":"10.1002\/cncr.26086","article-title":"Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer","volume":"117","author":"Tran","year":"2011","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.path.2026.01.010_bib42","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1200\/JCO.2009.23.3452","article-title":"Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial","volume":"28","author":"Roth","year":"2010","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.path.2026.01.010_bib43","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S1470-2045(15)00122-9","article-title":"FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study","volume":"16","author":"Cremolini","year":"2015","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.path.2026.01.010_bib44","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1038\/bjc.2015.173","article-title":"Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer","volume":"112","author":"Rowland","year":"2015","journal-title":"Br J Cancer"},{"issue":"34","key":"10.1016\/j.path.2026.01.010_bib45","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1200\/JCO.2015.63.2497","article-title":"Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer","volume":"33","author":"Kopetz","year":"2015","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.path.2026.01.010_bib46","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1158\/2159-8290.CD-16-0050","article-title":"Phase IB study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAFV600E mutation","volume":"6","author":"Hong","year":"2016","journal-title":"Cancer Discov"},{"issue":"4","key":"10.1016\/j.path.2026.01.010_bib47","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1200\/JCO.20.01994","article-title":"Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406)","volume":"39","author":"Kopetz","year":"2021","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.path.2026.01.010_bib48","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1056\/NEJMoa1908075","article-title":"Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer","volume":"381","author":"Kopetz","year":"2019","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.path.2026.01.010_bib49","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1200\/JCO.18.02459","article-title":"Binimetinib, encorafenib, and cetuximab triplet therapy for patients with BRAF V600E-mutant metastatic colorectal cancer: safety lead-in results from the phase III BEACON colorectal cancer study","volume":"37","author":"Van Cutsem","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.path.2026.01.010_bib50","doi-asserted-by":"crossref","DOI":"10.1177\/17588359231225037","article-title":"Treatment options for HER2-expressing colorectal cancer: updates and recent approvals","volume":"16","author":"Zheng-Lin","year":"2024","journal-title":"Ther Adv Med Oncol"},{"issue":"6","key":"10.1016\/j.path.2026.01.010_bib51","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(16)00150-9","article-title":"Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12\/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial","volume":"17","author":"Sartore-Bianchi","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.path.2026.01.010_bib52","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S1470-2045(18)30904-5","article-title":"Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study","volume":"20","author":"Meric-Bernstam","year":"2019","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.path.2026.01.010_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.modpat.2024.100654","article-title":"Evidence for unified assessment criteria of HER2 immunohistochemistry in colorectal carcinoma","volume":"38","author":"Evans","year":"2025","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.path.2026.01.010_bib54","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1038\/s41467-023-38032-4","article-title":"Final results of DESTINY-CRC01 investigating trastuzumab deruxtecan in patients with HER2-expressing metastatic colorectal cancer","volume":"14","author":"Yoshino","year":"2023","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.path.2026.01.010_bib55","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S1470-2045(24)00380-2","article-title":"Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial","volume":"25","author":"Raghav","year":"2024","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.path.2026.01.010_bib56","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S1470-2045(18)30434-0","article-title":"ASCO annual meeting","volume":"19","author":"Gourd","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.path.2026.01.010_bib57","article-title":"Molecular targeted therapy for metastatic colorectal cancer: current and evolving approaches","volume":"14","author":"Li","year":"2023","journal-title":"Front Pharmacol"},{"issue":"10","key":"10.1016\/j.path.2026.01.010_bib58","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1016\/S1470-2045(22)00541-1","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah","year":"2022","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.path.2026.01.010_bib59","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/jnci\/djx089","article-title":"ALK, ROS1, and NTRK rearrangements in metastatic colorectal cancer","volume":"109","author":"Pietrantonio","year":"2017","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.path.2026.01.010_bib60","series-title":"The MD Anderson manual of medical oncology","author":"Kantarjian","year":"2022"},{"issue":"3","key":"10.1016\/j.path.2026.01.010_bib61","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1007\/s11523-021-00815-4","article-title":"TRK fusion cancer: patient characteristics and survival analysis in the real-world setting","volume":"16","author":"Bazhenova","year":"2021","journal-title":"Target Oncol"},{"issue":"4","key":"10.1016\/j.path.2026.01.010_bib62","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S1470-2045(19)30856-3","article-title":"Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1\/2 clinical trials","volume":"21","author":"Hong","year":"2020","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.path.2026.01.010_bib63","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/2159-8290.CD-16-1237","article-title":"Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1)","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.path.2026.01.010_bib64","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/ng.2503","article-title":"Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas","volume":"45","author":"Palles","year":"2013","journal-title":"Nat Genet"},{"issue":"3","key":"10.1016\/j.path.2026.01.010_bib65","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S2468-1253(16)30014-0","article-title":"Somatic POLE proofreading domain mutation, immune response, and prognosis in colorectal cancer: a retrospective, pooled biomarker study","volume":"1","author":"Domingo","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.path.2026.01.010_bib66","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.celrep.2016.03.075","article-title":"Genomic correlates of immune-cell infiltrates in colorectal carcinoma","volume":"15","author":"Giannakis","year":"2016","journal-title":"Cell Rep"},{"issue":"5","key":"10.1016\/j.path.2026.01.010_bib67","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1016\/j.cell.2017.09.048","article-title":"Comprehensive analysis of hypermutation in human cancer","volume":"171","author":"Campbell","year":"2017","journal-title":"Cell"},{"issue":"6","key":"10.1016\/j.path.2026.01.010_bib68","doi-asserted-by":"crossref","first-page":"3304","DOI":"10.3390\/ijms25063304","article-title":"Targeting KRAS G12C mutation in colorectal cancer, a review: new arrows in the quiver","volume":"25","author":"Ros","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.path.2026.01.010_bib69","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa2212419","article-title":"Adagrasib with or without cetuximab in colorectal cancer with mutated KRAS G12C","volume":"388","author":"Yaeger","year":"2023","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.path.2026.01.010_bib70","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1001\/jamaoncol.2019.3616","article-title":"Circulating tumor DNA analyses as markers of recurrence risk and benefit of adjuvant therapy for stage III colon cancer","volume":"5","author":"Tie","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.path.2026.01.010_bib71","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1136\/gutjnl-2017-315852","article-title":"Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: a prospective biomarker study","volume":"68","author":"Tie","year":"2019","journal-title":"Gut"},{"key":"10.1016\/j.path.2026.01.010_bib72","doi-asserted-by":"crossref","first-page":"346ra92","DOI":"10.1126\/scitranslmed.aaf6219","article-title":"Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer","volume":"8","author":"Tie","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.path.2026.01.010_bib73","unstructured":"Tie J Cohen J, Wang Y, Lee M, et al. Serial circulating tumor DNA analysis as a prognostic marker and a real-time indicator of adjvuvant chemotherapy efficacy in stage III colon cancer Presented at: the American Society of Clinical Oncology Annual Symposium; Chicago, IL; June 1-5, 20, 2018."},{"key":"10.1016\/j.path.2026.01.010_bib74","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000010197","article-title":"The prognostic value of circulating cell-free DNA in breast cancer: a meta-analysis","volume":"97","author":"Tan","year":"2018","journal-title":"Medicine (Baltim)"},{"issue":"35","key":"10.1016\/j.path.2026.01.010_bib75","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.78.9032","article-title":"Circulating tumor DNA defined minimal residual disease in solid tumors: opportunities to accelerate the development of adjuvant therapies","volume":"36","author":"Dasari","year":"2018","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.path.2026.01.010_bib76","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1001\/jamaoncol.2019.0503","article-title":"Can circulating tumor DNA in early-stage colorectal cancer be more than a prognostic biomarker?","volume":"5","author":"Morris","year":"2019","journal-title":"JAMA Oncol"}],"container-title":["Surgical Pathology Clinics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875918126000103?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875918126000103?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T07:00:20Z","timestamp":1784530820000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875918126000103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":76,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1875918126000103"],"URL":"https:\/\/doi.org\/10.1016\/j.path.2026.01.010","relation":{},"ISSN":["1875-9181"],"issn-type":[{"value":"1875-9181","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oncogenicity and Therapeutic Implications of Molecular Biomarkers in Colorectal Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Surgical Pathology Clinics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.path.2026.01.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}